Home Cart 0 Sign in  
X

[ CAS No. 63071-10-3 ] {[proInfo.proName]}

,{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]}
3d Animation Molecule Structure of 63071-10-3
Chemical Structure| 63071-10-3
Chemical Structure| 63071-10-3
Structure of 63071-10-3 * Storage: {[proInfo.prStorage]}
Cart0 Add to My Favorites Add to My Favorites Bulk Inquiry Inquiry Add To Cart

Quality Control of [ 63071-10-3 ]

Related Doc. of [ 63071-10-3 ]

Alternatived Products of [ 63071-10-3 ]

Product Details of [ 63071-10-3 ]

CAS No. :63071-10-3 MDL No. :MFCD07437885
Formula : C6H6ClNO Boiling Point : -
Linear Structure Formula :- InChI Key :UEAIOHHGRGSGGJ-UHFFFAOYSA-N
M.W : 143.57 Pubchem ID :2763167
Synonyms :

Calculated chemistry of [ 63071-10-3 ]

Physicochemical Properties

Num. heavy atoms : 9
Num. arom. heavy atoms : 6
Fraction Csp3 : 0.17
Num. rotatable bonds : 1
Num. H-bond acceptors : 2.0
Num. H-bond donors : 1.0
Molar Refractivity : 35.37
TPSA : 33.12 Ų

Pharmacokinetics

GI absorption : High
BBB permeant : Yes
P-gp substrate : No
CYP1A2 inhibitor : No
CYP2C19 inhibitor : No
CYP2C9 inhibitor : No
CYP2D6 inhibitor : No
CYP3A4 inhibitor : No
Log Kp (skin permeation) : -6.73 cm/s

Lipophilicity

Log Po/w (iLOGP) : 1.57
Log Po/w (XLOGP3) : 0.63
Log Po/w (WLOGP) : 1.08
Log Po/w (MLOGP) : 0.49
Log Po/w (SILICOS-IT) : 1.85
Consensus Log Po/w : 1.12

Druglikeness

Lipinski : 0.0
Ghose : None
Veber : 0.0
Egan : 0.0
Muegge : 1.0
Bioavailability Score : 0.55

Water Solubility

Log S (ESOL) : -1.55
Solubility : 4.01 mg/ml ; 0.0279 mol/l
Class : Very soluble
Log S (Ali) : -0.9
Solubility : 18.1 mg/ml ; 0.126 mol/l
Class : Very soluble
Log S (SILICOS-IT) : -2.45
Solubility : 0.514 mg/ml ; 0.00358 mol/l
Class : Soluble

Medicinal Chemistry

PAINS : 0.0 alert
Brenk : 0.0 alert
Leadlikeness : 1.0
Synthetic accessibility : 1.3

Safety of [ 63071-10-3 ]

Signal Word:Warning Class:N/A
Precautionary Statements:P261-P305+P351+P338 UN#:N/A
Hazard Statements:H302-H315-H319-H335 Packing Group:N/A
GHS Pictogram:

Application In Synthesis of [ 63071-10-3 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

  • Upstream synthesis route of [ 63071-10-3 ]
  • Downstream synthetic route of [ 63071-10-3 ]

[ 63071-10-3 ] Synthesis Path-Upstream   1~24

  • 1
  • [ 24484-93-3 ]
  • [ 63071-10-3 ]
YieldReaction ConditionsOperation in experiment
98% With sodium tetrahydroborate; calcium chloride In tetrahydrofuran; methanol at 0℃; To a cooled (0 °C) solution of 24 (4.0 g, 23.3 mmol) and CaCl2 (10.3 g, 93.2 mmol) in dry MeOH-THF (2 : 1, 30 mL) was added portionwise NaBH4 (1.8 g, 46.6 mmol). After cooling to 0 °C, water was added to quench the reaction. The solvent were removed by evaporation and the residue was dissolved in water and extracted with CHCl3. The extracts was dried over MgSO4 and concentrated by evaporation to give 25 (3.3 g, 98 percent) as a white solid.
87% With sodium tetrahydroborate; calcium chloride In tetrahydrofuran; methanol at 0 - 20℃; for 48 h; Compound 6 was prepared according to a modified procedure (Comba, P., et al. inorg. Chem. 52, 6481-6501 (2013)). To a mixture of methanol (24 ml) and tetrahydrofurane (14 ml) were added 5 (4.1 g, 23.87 mmol) and calcium chloride (10.5 g, 95.48 mmol). The reaction mixture was cooled to 0 °C. Then, sodium borohydride (1.8 g, 47.74 mmol) was added portionwise. The resulting mixture was stirred at room temperature for 24 h. Then, the same amounts of methanol, tetrahydrofurane, calcium chloride, and sodium borohydride were added following the same procedure, and the reaction mixture was stirred for 24 h. After this time, water (80 ml) was added to the reaction mixture, which was stirred for 2 h. The product was extracted with EtOAc (3 χ 180 ml). The combined organic layer was washed with brine (100 ml), dried over MgS04 and concentrated to dryness under reduced pressure to afford 6 (3.0 g, 87percent) as a pale white solid. XH N MR (300 MHz, CDCI3): δ 8.38 (d, J = 5.5 Hz, 1H), 7.34 (s, 1H), 7.18 (dd, J = 5.5, 2.0 Hz, 1H), 4.71 (s, 2H), 4.19 (br s, 1H).13C N MR (75 M Hz, CDCIs): δ 161.6, 149.5, 145.0, 122.8, 121.1, 64.2. H RMS (ESI-TOF) calcd. for C6H6CIN NaO+ [M+Na]+ 166.0036, found: 166.0028.
Reference: [1] Chemical Communications, 2009, # 20, p. 2848 - 2850
[2] Bulletin of the Chemical Society of Japan, 2015, vol. 88, # 6, p. 784 - 791
[3] Synthetic Communications, 2005, vol. 35, # 24, p. 3187 - 3190
[4] Inorganic Chemistry, 2013, vol. 52, # 11, p. 6481 - 6501
[5] Angewandte Chemie - International Edition, 2017, vol. 56, # 23, p. 6483 - 6487[6] Angew. Chem., 2017, vol. 129, # 23, p. 6583 - 6587,5
[7] Patent: WO2017/102934, 2017, A1, . Location in patent: Page/Page column 23
[8] Heterocycles, 2000, vol. 53, # 4, p. 797 - 804
[9] Patent: US2004/186114, 2004, A1, . Location in patent: Page/Page column 61; 62; 64
[10] Patent: US5891889, 1999, A,
  • 2
  • [ 1121-76-2 ]
  • [ 420-37-1 ]
  • [ 63071-10-3 ]
YieldReaction ConditionsOperation in experiment
43%
Stage #1: at 20℃; for 2 h;
Stage #2: With ammonium peroxodisulfate In methanol; water for 1 h; Heating / reflux
4-Chloro-2-(hydroxymethyl)pyridine : A solution of 4-CHLOROPYRIDINE ASOXIDE (5 G, 38.6 MMOL) and TRIMETHYLOXONIUM TETRAFLUOROBORATE (5.94 G, 40.1 MMOI) in CH2CL2 (115 mL) was stirred for two hours at ambient temperature. The solvent was evaporated and the residue taken up in MeOH (115 mL) and heated to near boiling. Ammonium persulfate (1.76 G, 7.72 MMOL) dissolved in H2O (7.7 mL) was added and the mixture was heated to reflux for 30 min. A second portion of ammonium persulfate (0.88 G) in H2O (3.9 mL) was added and the mixture was refluxed for another 30 min. The solvent was evaporated and the residue was partitioned between CHZCTZ and aqueous Na2CO3 (10percent w/v). The organic layer was washed with H2O, dried over MgSO4 and evaporated leaving 2.4 G (43percent) of the title compound. 1H NMR (CDC13) 8 8.20 (d, 1H, J=5. 0 Hz, H-6); 7.31 (s, 1H, H-3); 7.04 (d, 1H, J=5. 0 Hz, H-5); 5.46 (s, LH, OH); 4.61 (s, 2H, CH2).
Reference: [1] Patent: WO2005/12323, 2005, A2, . Location in patent: Page/Page column 46
[2] Journal of Medicinal Chemistry, 1998, vol. 41, # 11, p. 1777 - 1788
[3] Patent: EP1422228, 2004, A1, . Location in patent: Page 199
  • 3
  • [ 3678-63-5 ]
  • [ 63071-10-3 ]
YieldReaction ConditionsOperation in experiment
18%
Stage #1: With 3-chloro-benzenecarboperoxoic acid In dichloromethane at 20℃; for 1.5 h;
Stage #2: at 100℃; for 1 h;
Stage #3: With sodium hydroxide; water In methanol at 0 - 20℃; for 1.5 h;
Manufacturing Example 51-1-1 (4-Chloro-pyridin-2-yl)-methanol; To a mixture of 4-chloro-2-picoline (1.0 g, 7.84 mmol) and dichloromethane (20 mL), was added m-chloroperbenzoic acid (3.5 g, 13.2 mmol) on an ice bath, which was stirred for 1.5 hours at room temperature. Water and sodium hydrogencarbonate were added to the reaction, followed by extraction with dichloromethane. The organic layer was separated, washed with water and saturated aqueous sodium chloride, dried over anhydrous magnesium sulfate, and filtered. Acetic anhydride (20 mL) was added to the residue obtained by concentrating the filtrate under a reduced pressure, and this was stirred for 1 hour at 100° C. The reaction mixture was cooled to room temperature and concentrated under a reduced pressure. A 5 N aqueous sodium hydroxide solution (1.57 mL, 7.87 mmol) was added to a mixture of the resulting residue and methanol (20 mL) on an ice bath, which was stirred for 1.5 hours at room temperature. Water was added to the mixture, which was then extracted with ethyl acetate. The organic layer was separated, washed with water and saturated aqueous sodium chloride, dried over anhydrous magnesium sulfate, and filtered. The filtrate was concentrated under a reduced pressure and the residue was purified by NH silica gel column chromatography (heptane:ethyl acetate=6:1) to obtain the title compound (200 mg, 18percent).1H-NMR Spectrum (CDCl3) δ (ppm): 4.76 (2H, s), 7.23-7.25 (1H, m), 7.32-7.33 (1H, m), 8.46 (1H, d, J=5.6 Hz).
Reference: [1] Patent: US2009/82403, 2009, A1, . Location in patent: Page/Page column 99
[2] Journal of Medicinal Chemistry, 1983, vol. 26, # 2, p. 218 - 222
[3] Pharmaceutical Bulletin, 1953, vol. 1, p. 293,296
[4] Pharmaceutical Bulletin, 1953, vol. 1, p. 293,296
  • 4
  • [ 63071-06-7 ]
  • [ 63071-10-3 ]
Reference: [1] Chemical and Pharmaceutical Bulletin, 2000, vol. 48, # 10, p. 1514 - 1518
[2] Patent: US2007/105904, 2007, A1, . Location in patent: Page/Page column 98
  • 5
  • [ 64064-56-8 ]
  • [ 63071-10-3 ]
Reference: [1] Synthetic Communications, 2005, vol. 35, # 24, p. 3187 - 3190
[2] Patent: US2009/44345, 2009, A1,
  • 6
  • [ 67-56-1 ]
  • [ 7379-35-3 ]
  • [ 63071-10-3 ]
YieldReaction ConditionsOperation in experiment
1.9 g
Stage #1: for 0.5 h; Reflux
Stage #2: for 2.5 h; Reflux
Concentrated sulfuric acid (0.25 mL) was added to a solution of 4-chloropyridine hydrochloride (3.00 g) in methanol (25 mL), followed by refluxing for 0.5 hours. An aqueous solution (25 mL) of ammonium persulfate (12.2 g) was added to the reaction mixture, followed by refluxing for 2.5 hours. The reaction mixture was cooled to room temperature, and the solvent was distilled off under reduced pressure. A sodium carbonate aqueous solution was added to the obtained residues, and the resultant product was extracted with ethyl acetate. The organic layer was dried over anhydrous sodium sulfate, and the solvent was distilled off under reduced pressure. The obtained residues were purified by silica gel column chromatography (hexane:ethyl acetate=1:1→0:1), whereby (4-chloro pyridin-2-yl)methanol (1.90 g) was obtained
Reference: [1] Patent: US2016/168139, 2016, A1, . Location in patent: Paragraph 0983-0985
  • 7
  • [ 880495-83-0 ]
  • [ 63071-10-3 ]
Reference: [1] Bioorganic and Medicinal Chemistry Letters, 2006, vol. 16, # 5, p. 1277 - 1281
  • 8
  • [ 5470-22-4 ]
  • [ 63071-10-3 ]
Reference: [1] Bioorganic and Medicinal Chemistry Letters, 2006, vol. 16, # 5, p. 1277 - 1281
[2] Angewandte Chemie - International Edition, 2017, vol. 56, # 23, p. 6483 - 6487[3] Angew. Chem., 2017, vol. 129, # 23, p. 6583 - 6587,5
[4] Patent: WO2017/102934, 2017, A1,
  • 9
  • [ 696-08-2 ]
  • [ 63071-10-3 ]
Reference: [1] Journal of Medicinal Chemistry, 1983, vol. 26, # 2, p. 218 - 222
[2] Chemical and Pharmaceutical Bulletin, 2000, vol. 48, # 10, p. 1514 - 1518
  • 10
  • [ 53750-66-6 ]
  • [ 63071-10-3 ]
Reference: [1] Heterocycles, 2000, vol. 53, # 4, p. 797 - 804
[2] Inorganic Chemistry, 2013, vol. 52, # 11, p. 6481 - 6501
  • 11
  • [ 63071-13-6 ]
  • [ 63071-10-3 ]
Reference: [1] Organic and Biomolecular Chemistry, 2014, vol. 12, # 30, p. 5781 - 5788
  • 12
  • [ 98-98-6 ]
  • [ 63071-10-3 ]
Reference: [1] Inorganic Chemistry, 2013, vol. 52, # 11, p. 6481 - 6501
[2] Bulletin of the Chemical Society of Japan, 2015, vol. 88, # 6, p. 784 - 791
  • 13
  • [ 931-19-1 ]
  • [ 63071-10-3 ]
Reference: [1] Chemical and Pharmaceutical Bulletin, 2000, vol. 48, # 10, p. 1514 - 1518
  • 14
  • [ 5470-66-6 ]
  • [ 63071-10-3 ]
Reference: [1] Chemical and Pharmaceutical Bulletin, 2000, vol. 48, # 10, p. 1514 - 1518
  • 15
  • [ 1121-76-2 ]
  • [ 63071-10-3 ]
Reference: [1] Synthetic Communications, 1989, vol. 19, # 1, 2, p. 317 - 326
  • 16
  • [ 856850-18-5 ]
  • [ 63071-10-3 ]
Reference: [1] Pharmaceutical Bulletin, 1953, vol. 1, p. 293,296
  • 17
  • [ 67-56-1 ]
  • [ 63071-10-3 ]
Reference: [1] Synthetic Communications, 1989, vol. 19, # 1, 2, p. 317 - 326
  • 18
  • [ 67-56-1 ]
  • [ 63071-10-3 ]
Reference: [1] Synthetic Communications, 1989, vol. 19, # 1, 2, p. 317 - 326
  • 19
  • [ 696-08-2 ]
  • [ 108-24-7 ]
  • [ 63071-10-3 ]
Reference: [1] Yakugaku Zasshi, 1957, vol. 77, p. 11,13[2] Chem.Abstr., 1957, p. 8745
  • 20
  • [ 63071-10-3 ]
  • [ 22282-65-1 ]
Reference: [1] Patent: WO2005/12323, 2005, A2,
  • 21
  • [ 63071-10-3 ]
  • [ 63071-13-6 ]
YieldReaction ConditionsOperation in experiment
59% With manganese(IV) oxide In chloroform for 2.5 h; Reflux A suspension of 25 (2.0 g, 13.9 mmol) and MnO2 (15 g) in dry CHCl3 (24 mL) was refluxed for 2.5 hr. After removal of MnO2 by filtration, the filtrate was concentrated by evaporation to give 26 (1.2 g, 59 percent) as a pale yellow solid.
425 mg With manganese(IV) oxide In ethyl acetate for 3.5 h; Reflux Manganese dioxide (3.03 g) was added to a solution of (4-chloropyridin-2-yl)methanol (1.00 g) obtained in Reference Example 21-7 (1) in ethyl acetate (20 mL), followed by refluxing for 3.5 hours. The reaction mixture was cooled to room temperature, the insoluble materials were filtered off, and the solvent was distilled off under reduced pressure. The obtained residues were purified by silica gel column chromatography (hexane:ethyl acetate=9:1→1:1), whereby 4-chloropicolinic aldehyde (425 mg) was obtained
Reference: [1] Chemical Communications, 2009, # 20, p. 2848 - 2850
[2] Inorganic Chemistry, 2013, vol. 52, # 11, p. 6481 - 6501
[3] Synthesis, 1996, # 8, p. 991 - 996
[4] Tetrahedron, 1997, vol. 53, # 24, p. 8257 - 8268
[5] Bulletin of the Chemical Society of Japan, 2015, vol. 88, # 6, p. 784 - 791
[6] Yakugaku Zasshi, 1957, vol. 77, p. 11,13[7] Chem.Abstr., 1957, p. 8745
[8] Patent: WO2007/25307, 2007, A2, . Location in patent: Page/Page column 306
[9] Patent: US2016/168139, 2016, A1, . Location in patent: Paragraph 0983; 0986; 0987
[10] Patent: WO2008/106139, 2008, A1, . Location in patent: Page/Page column 475
  • 22
  • [ 63071-10-3 ]
  • [ 100114-58-7 ]
Reference: [1] Patent: WO2012/142329, 2012, A1,
  • 23
  • [ 63071-10-3 ]
  • [ 119396-04-2 ]
Reference: [1] Patent: EP1188755, 2002, A1, . Location in patent: Page 53
  • 24
  • [ 63071-10-3 ]
  • [ 180748-30-5 ]
Reference: [1] Inorganic Chemistry, 2013, vol. 52, # 14, p. 8131 - 8143
[2] Bulletin of the Chemical Society of Japan, 2015, vol. 88, # 6, p. 784 - 791
Same Skeleton Products
Historical Records

Related Functional Groups of
[ 63071-10-3 ]

Chlorides

Chemical Structure| 3678-63-5

[ 3678-63-5 ]

4-Chloro-2-picoline

Similarity: 0.85

Chemical Structure| 98420-89-4

[ 98420-89-4 ]

4-Chloro-2-vinylpyridine

Similarity: 0.83

Chemical Structure| 5470-22-4

[ 5470-22-4 ]

4-Chloropicolinic acid

Similarity: 0.82

Chemical Structure| 209526-98-7

[ 209526-98-7 ]

(5-Chloropyridin-2-yl)methanol

Similarity: 0.82

Chemical Structure| 150054-50-5

[ 150054-50-5 ]

(4-Chloro-3,5-dimethylpyridin-2-yl)methanol

Similarity: 0.81

Alcohols

Chemical Structure| 209526-98-7

[ 209526-98-7 ]

(5-Chloropyridin-2-yl)methanol

Similarity: 0.82

Chemical Structure| 150054-50-5

[ 150054-50-5 ]

(4-Chloro-3,5-dimethylpyridin-2-yl)methanol

Similarity: 0.81

Chemical Structure| 126053-15-4

[ 126053-15-4 ]

4-Chloro-6,7-dihydro-5H-cyclopenta[b]pyridin-7-ol

Similarity: 0.78

Chemical Structure| 113209-90-8

[ 113209-90-8 ]

(4-Chloro-5-fluoropyridin-2-yl)methanol

Similarity: 0.78

Chemical Structure| 60588-81-0

[ 60588-81-0 ]

(3-Chloropyridin-2-yl)methanol

Similarity: 0.78

Related Parent Nucleus of
[ 63071-10-3 ]

Pyridines

Chemical Structure| 3678-63-5

[ 3678-63-5 ]

4-Chloro-2-picoline

Similarity: 0.85

Chemical Structure| 98420-89-4

[ 98420-89-4 ]

4-Chloro-2-vinylpyridine

Similarity: 0.83

Chemical Structure| 5470-22-4

[ 5470-22-4 ]

4-Chloropicolinic acid

Similarity: 0.82

Chemical Structure| 209526-98-7

[ 209526-98-7 ]

(5-Chloropyridin-2-yl)methanol

Similarity: 0.82

Chemical Structure| 150054-50-5

[ 150054-50-5 ]

(4-Chloro-3,5-dimethylpyridin-2-yl)methanol

Similarity: 0.81